AbbVie Investigates One-Dose Therapy for Alzheimer’s with Voyager Therapeutics Collaboration
By Natasha Piper
Pharma Deals Review: Vol 2018 Issue 3 (Table of Contents)
Published: 10 Mar-2018
DOI: 10.3833/pdr.v2018.i3.2309 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
AbbVie has announced a collaboration with Voyager Therapeutics to develop tau-targeted vectorised antibodies for the treatment of Alzheimer’s disease (AD) and potentially other neurodegenerative diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS